Literature DB >> 1849359

Oncogene amplification in breast cancer.

M Donovan-Peluso1, A M Contento, H Tobon, B Ripepi, J Locker.   

Abstract

To refine the analysis of gene amplification in breast cancer, the authors have developed sensitive methods that can be used to screen nucleic acid prepared from a variety of sources. In their analysis, Southern hybridization and DNA dot-blot analysis were used to screen 49 breast cancer DNAs for Myc, Neu, and Int-2 gene amplification. The analysis detected minimal one extra gene copy) as well as expanded (two or more extra gene copies) gene amplifications, and in addition, distinguished between gene amplification and aneuploidy as the cause of extra gene copies. These quantitative methods were adapted to patient specimens routinely available in the anatomic pathology laboratory, including fresh tumor tissue, tumor nuclei discarded during estrogen receptor analysis, and paraffin blocks. One minimal gene amplification was found in three cases of intraductal cancer. Of 25 cases of nonmetastatic invasive cancer, 28% had at least one extra Myc gene, whereas 24% had Neu, and 21% had Int-2 gene amplification. Of 21 cases of metastatic invasive cancer, 43% had Myc, 43% had Neu, and 40% had Int-2 gene amplification. Among the nonmetastatic cancers, 47% had one, 12% had two, and 4% had three amplified genes. Within the metastatic cancers, 48% had one, 28% had two, and 5% had three amplified genes. Our data suggest relationships between tumor progression and both incidence and size of Myc, Neu, and Int-2 gene amplification.

Entities:  

Mesh:

Year:  1991        PMID: 1849359      PMCID: PMC1886106     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  37 in total

1.  Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas.

Authors:  I Garcia; P Y Dietrich; M Aapro; G Vauthier; L Vadas; E Engel
Journal:  Cancer Res       Date:  1989-12-01       Impact factor: 12.701

2.  Characterization and chromosome assignment of the human homolog of int-2, a potential proto-oncogene.

Authors:  G Casey; R Smith; D McGillivray; G Peters; C Dickson
Journal:  Mol Cell Biol       Date:  1986-02       Impact factor: 4.272

3.  Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1.

Authors:  H Tsuda; S Hirohashi; Y Shimosato; T Hirota; S Tsugane; H Yamamoto; N Miyajima; K Toyoshima; T Yamamoto; J Yokota
Journal:  Cancer Res       Date:  1989-06-01       Impact factor: 12.701

4.  Amplification of the proto-neu oncogene facilitates oncogenic activation by a single point mutation.

Authors:  M C Hung; D H Yan; X Y Zhao
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

5.  The mouse homolog of the hst/k-FGF gene is adjacent to int-2 and is activated by proviral insertion in some virally induced mammary tumors.

Authors:  G Peters; S Brookes; R Smith; M Placzek; C Dickson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

6.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

7.  Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene.

Authors:  W J Muller; E Sinn; P K Pattengale; R Wallace; P Leder
Journal:  Cell       Date:  1988-07-01       Impact factor: 41.582

8.  Sequence, topography and protein coding potential of mouse int-2: a putative oncogene activated by mouse mammary tumour virus.

Authors:  R Moore; G Casey; S Brookes; M Dixon; G Peters; C Dickson
Journal:  EMBO J       Date:  1986-05       Impact factor: 11.598

9.  A human chromosome 8 region with abnormalities in B cell, HTLV-I+ T cell and c-myc amplified tumours.

Authors:  L Mengle-Gaw; T H Rabbitts
Journal:  EMBO J       Date:  1987-07       Impact factor: 11.598

10.  c-erbB-2/c-erbA co-amplification indicative of lymph node metastasis, and c-myc amplification of high tumour grade, in human breast carcinoma.

Authors:  M Tavassoli; P Quirke; F Farzaneh; N J Lock; L V Mayne; N Kirkham
Journal:  Br J Cancer       Date:  1989-10       Impact factor: 7.640

View more
  4 in total

1.  Influence of calorie restriction on oncogene expression and DNA synthesis during liver regeneration.

Authors:  Y Himeno; R W Engelman; R A Good
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

Review 2.  Molecular cytogenetics of multiple drug resistance.

Authors:  P V Schoenlein
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

3.  Concurrent abnormal expression of ERBB-2, EGFR, and p53 genes and clinical disease progression of breast carcinoma.

Authors:  D W Visscher; R Castellani; S M Wykes; F H Sarkar; M E Hussain
Journal:  Breast Cancer Res Treat       Date:  1993-12       Impact factor: 4.872

4.  Estrogen receptor, c-erbB-2 and nm23/NDP kinase expression in the intraductal and invasive components of human breast cancers.

Authors:  S Kobayashi; H Iwase; Y Itoh; H Fukuoka; H Yamashita; T Kuzushima; H Iwata; A Masaoka; N Kimura
Journal:  Jpn J Cancer Res       Date:  1992-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.